Original Report

The value of anticancer drugs in metastatic castrate-resistant prostate cancer: economic tools for the community oncologist


 

Background Community oncologists need a simplified methodology for assessing the value of anticancer drugs. In the United States and Europe, costs of anticancer drug were previously estimated at US$50,000 to >US$100,000 per quality-adjusted life-year (QALY). The National Institute for Health and Care Excellence in the United Kingdom states that the average cost-effectiveness ratios intervention of >US$50,000 per QALY must be questioned.

Objectives To design a drug model to estimate the amount in United States dollars (US$) paid for life-year gain (LYG) and QALY, and to apply that model in the treatment of chemo-naïve and chemo-treated patients with castrate-resistant metastatic prostate cancer (mCRPC).

Methods Cost per LYG (cost/LYG) was compared with cost per probability of survival (cost/PoS) calculated as [1.0 minus HR]. Results were expressed in relative values (RV) calculated as US$50,000 or US$100,000 per cost/outcome.

Results In patients with mCRPC, generic docetaxel demonstrated the lowest cost/LYG (US$26,330), lowest cost/ PoS (US$21,942), and the highest RV (3.80-4.56). Cost/LYG of sipuleucel-T was US$272,195, with an RV of 0.37. Significant variation between cost/LYG and cost/ PoS was noted among drugs with borderline survival and HR. In previously treated patients, the cost/LYG of cabazitaxel was US$207,240; of abiraterone, US$194,087; enzalutamide, US$223,500; and radium-223 dichloride, US$230,000, all with RVs <0.5.

Conclusions A simplified drug model to weigh cost, survival, and HR with imposed limits on cost/outcome was proposed and applied to patients with mCRPC. The results among that patient population suggested that generic docetaxel had the lowest costs, cost/outcome and the highest RV. Sipuleucel-T, abiraterone, enzalutamide, radium-223 dichloride, and cabazitaxel were overpriced for their values. Drugs with RVs of <0.5 should be scrutinized, costs negotiated, or other drugs considered, and those with RVs of <0.25, rejected.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Adding trebananib increased toxicity for metastatic RCC patients
MDedge Hematology and Oncology
Impact of bladder volume on radiation dose to the rectum in the definitive treatment of prostate cancer
MDedge Hematology and Oncology
Genomic oncology: moving beyond the tip of the iceberg
MDedge Hematology and Oncology
Low-risk prostate cancer: Replace immediate intervention with immediate contemplation
MDedge Hematology and Oncology
Individualized approach improves surveillance after renal cell carcinoma resection
MDedge Hematology and Oncology
Noncanonical Wnt signaling implicated in antiandrogen-resistant prostate cancer
MDedge Hematology and Oncology
No survival difference between continuous and intermittent ADT
MDedge Hematology and Oncology
Prostate cancer: Men with comorbidity may be better off with no ADT
MDedge Hematology and Oncology
VIDEO: Long-term responses possible in advanced kidney cancer?
MDedge Hematology and Oncology
Self-assessed mental health scores tied to radical cystectomy complications
MDedge Hematology and Oncology